COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00686075




Registration number
NCT00686075
Ethics application status
Date submitted
23/05/2008
Date registered
29/05/2008
Date last updated
26/09/2014

Titles & IDs
Public title
A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants
Scientific title
A Phase 1/2a, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-old Children and in 2 Month-old Infants
Secondary ID [1] 0 0
MI-CP178
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - MEDI-534, Cohort 1
Other interventions - Placebo, Cohort 1
Other interventions - MEDI-534, Cohort 2
Other interventions - Placebo, Cohort 2
Other interventions - MEDI-534, Cohort 3
Other interventions - Placebo, Cohort 3
Other interventions - MEDI-534, Cohort 4
Other interventions - Placebo, Cohort 4
Other interventions - MEDI-534, Cohort 5
Other interventions - Placebo, Cohort 5

Experimental: MEDI-534, Cohort 1 - Participants aged 6 to less than (<) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.

Placebo Comparator: Placebo, Cohort 1 - Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.

Experimental: MEDI-534, Cohort 2 - Participants aged 6 to <24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.

Placebo Comparator: Placebo, Cohort 2 - Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.

Experimental: MEDI-534, Cohort 3 - Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.

Placebo Comparator: Placebo, Cohort 3 - Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.

Experimental: MEDI-534, Cohort 4 - Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.

Placebo Comparator: Placebo, Cohort 4 - Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.

Experimental: MEDI-534, Cohort 5 - Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.

Placebo Comparator: Placebo, Cohort 5 - Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.


Other interventions: MEDI-534, Cohort 1
Participants aged 6 to less than (<) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.

Other interventions: Placebo, Cohort 1
Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.

Other interventions: MEDI-534, Cohort 2
Participants aged 6 to <24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.

Other interventions: Placebo, Cohort 2
Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.

Other interventions: MEDI-534, Cohort 3
Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.

Other interventions: Placebo, Cohort 3
Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.

Other interventions: MEDI-534, Cohort 4
Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.

Other interventions: Placebo, Cohort 4
Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.

Other interventions: MEDI-534, Cohort 5
Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.

Other interventions: Placebo, Cohort 5
Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Solicited Symptoms After Dose 1 - Solicited symptoms were predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms included fever greater than or equal to (>=) 100.4 degrees Fahrenheit (F), runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, oropharyngeal inflammation (laryngitis), and epistaxis.
Timepoint [1] 0 0
Within 28 days after Dose 1
Primary outcome [2] 0 0
Number of Participants With Solicited Symptoms After Dose 2 - Solicited symptoms were predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms included fever >=100.4 degrees F, runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, oropharyngeal inflammation (laryngitis), and epistaxis.
Timepoint [2] 0 0
Within 28 days after Dose 2
Primary outcome [3] 0 0
Number of Participants With Solicited Symptoms After Dose 3 - Solicited symptoms were predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms included fever >=100.4 degrees F, runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, oropharyngeal inflammation (laryngitis), and epistaxis.
Timepoint [3] 0 0
Within 28 days after Dose 3
Primary outcome [4] 0 0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Dose 1 - An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAEs) for Dose 1 are events between administration of Dose 1 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TEAEs (spontaneously reported events) after Dose 1 were reported.
Timepoint [4] 0 0
Within 28 days after Dose 1
Primary outcome [5] 0 0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Dose 2 - An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-Emergent Adverse Events (TEAEs) for Dose 2 are events between administration of Dose 2 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TEAEs (spontaneously reported events) after Dose 2 were reported.
Timepoint [5] 0 0
Within 28 days after Dose 2
Primary outcome [6] 0 0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Dose 3 - An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-Emergent Adverse Events (TEAEs) for Dose 3 are events between administration of Dose 3 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TEAEs (spontaneously reported events) after Dose 3 were reported.
Timepoint [6] 0 0
Within 28 days after Dose 3
Primary outcome [7] 0 0
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) After Dose 1 - An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events between administration of Dose 1 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) after Dose 1 were reported.
Timepoint [7] 0 0
Within 28 days after Dose 1
Primary outcome [8] 0 0
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) After Dose 2 - An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events between administration of Dose 2 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) after Dose 2 were reported.
Timepoint [8] 0 0
Within 28 days after Dose 2
Primary outcome [9] 0 0
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) After Dose 3 - An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events between administration of Dose 3 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) after Dose 3 were reported.
Timepoint [9] 0 0
Within 28 days after Dose 3
Primary outcome [10] 0 0
Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) After Dose 1 - An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea.
Timepoint [10] 0 0
Within 28 days after Dose 1
Primary outcome [11] 0 0
Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) After Dose 2 - An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea.
Timepoint [11] 0 0
Within 28 days after Dose 2
Primary outcome [12] 0 0
Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) After Dose 3 - An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea.
Timepoint [12] 0 0
Within 28 days after Dose 3
Secondary outcome [1] 0 0
Number of Participants Who Shed Vaccine-Type Virus - Nasal wash specimens were collected to assess vaccine virus recovery in the upper respiratory tract on 7, 12 and 28 days after each dosing.
Timepoint [1] 0 0
7, 12 and 28 days after Dose 1, 2 and 3
Secondary outcome [2] 0 0
Percentage of Participants With a Seroresponse to Respiratory Syncytial Virus (RSV) and Human Parainfluenza Virus Type 3 (hPIV3) After Dose 3 - Seroresponse was defined as a >=4-fold rise from Baseline in neutralizing antibody titer, regardless of Baseline serostatus. Respiratory Syncytial Virus (RSV) and hPIV3 antibody titers were determined by using microneutralization assay and hemagglutination inhibition assay, respectively. Clopper-pearson exact confidence interval was reported.
Timepoint [2] 0 0
Day 28 after Dose 3
Secondary outcome [3] 0 0
Genotypic Stability of Recovered Vaccine-Type Virus - Nasal wash samples with vaccine-type virus were evaluated for genotypic stability, defined as the presence of the entire RSV-Fusion (RSV F) insert based on the RSV F sequence results. If the insert was absent or truncated, the recovered virus was counted as genotypically unstable. Nasal wash samples were categorized as genotypically stable, genotypically unstable or undetermined genotypic stability.
Timepoint [3] 0 0
Within 28 days after any dose
Secondary outcome [4] 0 0
Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) Through 365 Days After Randomization - An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea. MA-LRIs occurring within 28 days post any dose and after 28 days post any dose were summarized separately.
Timepoint [4] 0 0
Day 0 to Day 365
Secondary outcome [5] 0 0
Number of Participants With Significant New Medical Conditions (SNMCs) Through 365 Days After Randomization - An SNMC was a newly diagnosed medical condition that was of a chronic, ongoing nature and was assessed by the investigator as medically significant. Examples of SNMCs include diabetes, asthma, autoimmune disease (for example, lupus, rheumatoid arthritis), and neurological disease (for example, epilepsy, autism).
Timepoint [5] 0 0
Day 0 to Day 365
Secondary outcome [6] 0 0
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) Through 365 Days After Randomization - An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events after administration of drug which were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) within 365 days after randomization were reported.
Timepoint [6] 0 0
Day 0 to Day 365

Eligibility
Key inclusion criteria
- Male or female whose age on the day of randomization falls within one of the two age
groups:

6 to less than (<) 24 months (more than [>] 6 months of age and not yet reached their
2nd year birthday), Cohorts 1 and 2 2 months (+/- 4 weeks), Cohorts 3, 4, and 5

- Cohorts 1 and 2 only: Subject is seronegative to both Respiratory Syncytial Virus
(RSV) and human Parainfluenza Virus Type 3 (hPIV3) at Screening

- Subject whose gestational age was greater than or equal to (>=) 36 weeks

- Subject is in general good health with normal growth (that is, body weight greater
than (>) third percentile per world health organization [WHO] simplified
weight-per-age field tables

- Subject's legal representative is available by telephone

- Written informed consent and Health Insurance Portability and Accountability Act
(HIPAA) authorization (if applicable) obtained from the subject's legal representative

- Subject's legal representative is able to understand and comply with the requirements
of the protocol as judged by the investigator

- Subject is available to complete the follow-up period 1-year after receipt of the
first dose of study vaccine

- Subject's legal representative must be willing and able to bring the subject to the
study site for evaluation of respiratory illness in accordance with the protocol.
Minimum age
2 Months
Maximum age
23 Months
Gender
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- Any fever (>=100.4 degrees Fahrenheit [>=38.0 degrees Celsius], regardless of route)
or lower respiratory illness within 7 days prior to randomization

- Moderate or severe nasal congestion that in the investigator's opinion could interfere
with intranasal delivery of study vaccine

- Acute illness (defined as the presence of moderate or severe signs and symptoms) at
the time of randomization

- Any drug therapy (chronic or other) within 7 days prior to randomization or expected
receipt through the protocol-specified blood collection 28 days after each study
vaccine dosing, except that infrequent use of over-the-counter medications for the
systemic treatment of common childhood symptoms (that is, pain relievers,
decongestants or cough suppressants) are permitted according to the judgment of the
investigator

- Any current or expected receipt of immunosuppressive agents including steroids (>=2
milligram per kilogram [mg/kg] per day of prednisone or its equivalent, or >=20
milligram per day [mg/day] if the subject weighs >10 kilogram [kg], given daily or on
alternate days for >=14 days); children in this category should not receive study
vaccine until immunosuppressive agents including corticosteroid therapy have been
discontinued for >=30 days; the use of topical steroids is permitted according to the
judgment of the investigator

- History of receipt of blood transfusion or expected receipt through the
protocol-specified blood collection at 28 days after final study dosing

- History of receipt of immunoglobulin products or expected receipt through the
protocol-specified blood collection at 28 days after final study dosing

- Receipt of any investigational drug within 60 days prior to randomization or expected
receipt through 180 days after final study dosing

- Receipt of any live virus vaccine (excluding oral polio vaccine and rotavirus vaccine)
within 28 days prior to randomization or expected receipt within a 28-day window
around any study vaccine dose

- Receipt of any inactivated (that is, non-live) vaccine or oral polio vaccine or
rotavirus vaccine within 14 days prior to randomization or expected receipt within a
14-day window around any study vaccine dose

- Known or suspected immunodeficiency, including human immunodeficiency virus (HIV)
infection

- Expected to be living in the same home or enrolled in the same classroom at day care
with infants <6 months within 28 days after each dose

- Living in a household with another child who is concurrently enrolled in a study of a
live viral vaccine (including this study)

- Expected contact with a pregnant caregiver within 28 days after each dose

- A household contact who is immunocompromised; the subject should also avoid close
contact with immunocompromised individuals for at least 28 days after any study
vaccine dose

- Expected household contact within 28 days after each dose with a health care provider
for immunocompromised subjects or who is a day care provider for infants under the age
of 6 months

- History of allergic reaction to any component of the study vaccine

- Previous medical history, or evidence, of an intercurrent or chronic illness that, in
the opinion of the investigator, may compromise the safety of the subject

- Known or suspected active or chronic hepatitis infection

- History of medical diagnosis of asthma, reactive airway disease, wheezing requiring
medication, cystic fibrosis, bronchopulmonary dysplasia, chronic pulmonary disease,
medically confirmed apnea, hospitalization for respiratory illness or mechanical
ventilation for respiratory illness (excludes elective mechanical ventilation during
surgery for subjects in Cohorts 1 and 2)

- Family member or household contact who is an employee of the research center or
otherwise involved with the conduct of the study

- Any condition that, in the opinion of the investigator, might interfere with study
vaccine evaluation.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1/Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,QLD,SA,WA
Recruitment hospital [1] 0 0
Research Site - Garran
Recruitment hospital [2] 0 0
Research Site - Herston
Recruitment hospital [3] 0 0
Research Site - North Adelaide
Recruitment hospital [4] 0 0
Research Site - Subiaco
Recruitment postcode(s) [1] 0 0
2605 - Garran
Recruitment postcode(s) [2] 0 0
4006 - Herston
Recruitment postcode(s) [3] 0 0
5006 - North Adelaide
Recruitment postcode(s) [4] 0 0
6008 - Subiaco
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
Nevada
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Utah
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
United States of America
State/province [24] 0 0
West Virginia
Country [25] 0 0
Brazil
State/province [25] 0 0
Rio Grande do Sul
Country [26] 0 0
Brazil
State/province [26] 0 0
SP
Country [27] 0 0
Brazil
State/province [27] 0 0
Porto alegre - RS
Country [28] 0 0
Brazil
State/province [28] 0 0
Porto Alegre/RS
Country [29] 0 0
Brazil
State/province [29] 0 0
Ribeirao Preto - SP
Country [30] 0 0
Brazil
State/province [30] 0 0
Sao Paulo - SP
Country [31] 0 0
Brazil
State/province [31] 0 0
São Paulo
Country [32] 0 0
Canada
State/province [32] 0 0
Ontario
Country [33] 0 0
Canada
State/province [33] 0 0
Saskatchewan
Country [34] 0 0
Finland
State/province [34] 0 0
Helsinki
Country [35] 0 0
Finland
State/province [35] 0 0
Jarvenpaa
Country [36] 0 0
Finland
State/province [36] 0 0
Kokkola
Country [37] 0 0
Finland
State/province [37] 0 0
Kuopio
Country [38] 0 0
Finland
State/province [38] 0 0
Lahti
Country [39] 0 0
Finland
State/province [39] 0 0
Oulu
Country [40] 0 0
Finland
State/province [40] 0 0
Pori
Country [41] 0 0
Finland
State/province [41] 0 0
Tampere
Country [42] 0 0
Finland
State/province [42] 0 0
Turku
Country [43] 0 0
Germany
State/province [43] 0 0
Berlin
Country [44] 0 0
Germany
State/province [44] 0 0
Freiburg
Country [45] 0 0
Germany
State/province [45] 0 0
Mainz
Country [46] 0 0
Israel
State/province [46] 0 0
Netanya
Country [47] 0 0
South Africa
State/province [47] 0 0
Gauteng
Country [48] 0 0
South Africa
State/province [48] 0 0
Western Cape
Country [49] 0 0
Spain
State/province [49] 0 0
Andalucia
Country [50] 0 0
Spain
State/province [50] 0 0
Andalucía
Country [51] 0 0
Spain
State/province [51] 0 0
Cataluna
Country [52] 0 0
Spain
State/province [52] 0 0
Comunidad Valenciana
Country [53] 0 0
Spain
State/province [53] 0 0
Galicia
Country [54] 0 0
Spain
State/province [54] 0 0
Madrid, Communidad de
Country [55] 0 0
Spain
State/province [55] 0 0
Pais Vasco
Country [56] 0 0
Spain
State/province [56] 0 0
Esplugues de Llobregat
Country [57] 0 0
Spain
State/province [57] 0 0
Madrid
Country [58] 0 0
Spain
State/province [58] 0 0
Málaga
Country [59] 0 0
Spain
State/province [59] 0 0
Valencia

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
MedImmune LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Primary objective of this study is to describe the safety and tolerability of multiple doses
of MEDI-534 in children 6 to less than (<) 24 months of age and in infants 2 months of age.
Trial website
https://clinicaltrials.gov/show/NCT00686075
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Elissa Malkin, D.O.
Address 0 0
MedImmune LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications